63V Stock Chart & Stats
€0.02
€0.00(0.00%)
At close: 4:00 PM EST
€0.02
€0.00(0.00%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.05
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€6.01M
Enterprise Value€8.63
Total Cash (Recent Filing)€3.34M
Total Debt (Recent Filing)€197.07K
Price to Earnings (P/E)―
Beta-2.34
Next Earnings
Sep 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding2,287,311,300
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.20
Price to Sales (P/S)2.08
P/FCF Ratio-0.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€56.87K
Bulls Say, Bears Say
Bulls Say
Revenue AccelerationThe sharp multi-year revenue increase indicates growing adoption of Verici Dx's transplant diagnostics. Sustained commercial uptake could expand the installed customer base and create a stronger platform for future operating leverage.
Positive Gross ProfitPositive and expanding gross profit shows that the underlying diagnostic offering generates value above direct costs. If maintained as volumes scale, this provides a foundation for improving margins and reducing the gap to operating break-even.
Low LeverageModest and declining debt limits interest and refinancing pressure compared with a highly leveraged business. Positive equity also provides some balance-sheet support while the company works to commercialize its tests and improve profitability.
Bears Say
Persistent Operating LossesRecurring large operating and net losses show that revenue growth has not yet translated into a sustainable business model. Continued losses may delay self-funded expansion and increase the need for cost reductions or external capital.
Worsening Cash BurnCash consumption is increasing despite higher revenue, indicating that commercialization and operating costs remain ahead of internally generated funds. If this persists, financing dependence could constrain investment and expose shareholders to dilution.
Shrinking Asset BaseA declining asset base alongside continuing losses suggests that financial resources are being depleted faster than they are replenished. This reduces resilience and increases execution risk if the company must fund research, sales expansion, or working capital.
Verici Dx Plc News
63V FAQ
What was Verici Dx Plc’s price range in the past 12 months?
Verici Dx Plc lowest stock price was <€0.01 and its highest was €0.05 in the past 12 months.
What is Verici Dx Plc’s market cap?
Verici Dx Plc’s market cap is €6.01M.
When is Verici Dx Plc’s upcoming earnings report date?
Verici Dx Plc’s upcoming earnings report date is Sep 14, 2026 which is in 15 days.
How were Verici Dx Plc’s earnings last quarter?
Verici Dx Plc released its earnings results on Jun 29, 2026. The company reported -€0.002 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Verici Dx Plc overvalued?
According to Wall Street analysts Verici Dx Plc’s price is currently Overvalued.
Does Verici Dx Plc pay dividends?
Verici Dx Plc does not currently pay dividends.
What is Verici Dx Plc’s EPS estimate?
Verici Dx Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Verici Dx Plc have?
Verici Dx Plc has 2,287,311,300 shares outstanding.
What happened to Verici Dx Plc’s price movement after its last earnings report?
Verici Dx Plc reported an EPS of -€0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 11.429%.
Which hedge fund is a major shareholder of Verici Dx Plc?
Currently, no hedge funds are holding shares in DE:63V
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Verici Dx Plc
Verici Dx plc is an immuno-diagnostics company primarily focused on the kidney transplantation sector. The firm specializes in creating both predictive and diagnostic assays for patients who have undergone kidney transplants. Its development pipeline features Clarava, a pre-transplant tool designed to forecast the likelihood of early acute rejection; Tuteva, a post-transplant assessment focusing on acute cellular rejection; and Protega, an innovative liquid biopsy aiming to predict the risk of fibrosis and eventual graft failure. Established in 2020, Verici Dx plc maintains its headquarters in Penarth, United Kingdom.
Technical Analysis
EKF Diagnostics Holdings
―
Genedrive
―
Oxford BioDynamics
―
Renalytix
―
Abingdon Health PLC
―